[Comment] Bevacizumab in adjuvant treatment of non-small-cell lung cancer
Outcomes in early-stage non-small-cell lung cancer (NSCLC) are infamously poor. In the ANITA trial of patients with stage IB –IIIA disease,1 median overall survival for after surgical resection was 43·7 months. Use of adjuvant chemotherapy improved outcome but median overall survival was still only 65·7 months, and meta-analyses2 of NSCLC adjuvant chemotherapy trials suggest a relative survival benefit of just 5% at 5 years.2 When Heather Wakelee and colleagues designed the E1505 trial in 2007, the results of which are reported in The Lancet Oncology, there was a massive unmet need for better therapeutics. (Source: The Lancet Oncology)
Source: The Lancet Oncology - November 9, 2017 Category: Cancer & Oncology Authors: Jared Weiss Tags: Comment Source Type: research
[Comment] Quality of life: an important element of treatment value
In the era of platinum-based chemotherapy, attempts to improve the quality of life (QOL) of patients with advanced non-small-cell lung cancer (NSCLC) using a less toxic treatment than the existing standard therapy were often disappointing. In a randomised trial1 comparing cisplatin-based treatment to a so-called platinum-free combination chemotherapy, the goal of improving QOL was not met. The lesson learned was that in patients with a disease often associated with serious symptoms, reduction of treatment-related toxicity is not enough to improve global QOL, and more effective control of disease is needed to achieve a posi...
Source: The Lancet Oncology - November 9, 2017 Category: Cancer & Oncology Authors: Massimo Di Maio Tags: Comment Source Type: research
[Articles] Incomplete excision of cervical precancer as a predictor of treatment failure: a systematic review and meta-analysis
The risk of residual or recurrent CIN2+ is significantly greater with involved margins on excisional treatment; however, high-risk HPV post-treatment predicts treatment failure more accurately than margin status. (Source: The Lancet Oncology)
Source: The Lancet Oncology - November 7, 2017 Category: Cancer & Oncology Authors: Marc Arbyn, Charles W E Redman, Freija Verdoodt, Maria Kyrgiou, Menelaos Tzafetas, Sadaf Ghaem-Maghami, Karl-Ulrich Petry, Simon Leeson, Christine Bergeron, Pekka Nieminen, Jean Gondry, Olaf Reich, Esther L Moss Tags: Articles Source Type: research
[Comment] Questioning the value of margin status in treated cervical precancer
Cervical carcinoma is the third most common cancer in women worldwide, with more than 500 000 diagnoses and 250 000 deaths annually.1 Persistent infection with human papillomavirus (HPV) can lead to high-grade neoplastic changes (cervical intraepithelial neoplasia [CIN]) that, if untreated, can progress to invasive disease within 10–15 years.2 Knowledge of cervical cancer pathogen esis and the natural history of its precursor lesion (CIN grade 3 [CIN3]) together with a suitable test (the Papanicolaou smear) and excisional treatments, has led to the implementation of successful screening programmes in many countries....
Source: The Lancet Oncology - November 7, 2017 Category: Cancer & Oncology Authors: Paul A Cohen Tags: Comment Source Type: research
[Articles] Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial
The GOLD study did not meet its primary objective of showing a significant improvement in overall survival with olaparib in the overall or ATM-negative population of Asian patients with advanced gastric cancer. The study generated informative efficacy and safety data regarding the use of olaparib in combination with a chemotherapeutic agent and provides a foundation for future studies in this difficult-to-treat patient population. (Source: The Lancet Oncology)
Source: The Lancet Oncology - November 2, 2017 Category: Cancer & Oncology Authors: Yung-Jue Bang, Rui-Hua Xu, Keisho Chin, Keun-Wook Lee, Se Hoon Park, Sun Young Rha, Lin Shen, Shukui Qin, Nong Xu, Seock-Ah Im, Gershon Locker, Phil Rowe, Xiaojin Shi, Darren Hodgson, Yu-Zhen Liu, Narikazu Boku Tags: Articles Source Type: research
